An interventional study of fMRI-based neurofeedback in Depression, Unipolar, sponsored by Maastricht University Medical Center. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Depressive Disorder with a site in Netherlands — 7 open to participants now, 9 under way, none of them phase 3. Depressive Disorder · Netherlands.
Among the 18 studies in Depressive Disorder with a site in Netherlands, this one is the 9th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 with no phase, and was the 12th registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →7 of the 18 studies in Depressive Disorder with a site in Netherlands are open now. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Arkin · Sites in Netherlands
Ages 18–65
Universiteit Leiden · Sites in Netherlands
Ages 18–65
University Medical Center Groningen · Sites in Netherlands
Ages 18+
UMC Utrecht · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 87 across 691 interventional studies indexed under Depressive Disorder.
Median enrollment 151 across the 16 interventional studies, 216 across the 2 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
Maastricht University Medical Center has 2 studies filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
4 of the studies in Depressive Disorder with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07022184Radboud University Medical CenterLifestyle Intervention for Symptoms of Depression wIth App Support in General Practice | 2026-11 |
| NCT05640089Maastricht University Medical CenterFMRI-neurofeedback in Depression | 2027-04-30 |
| NCT07950800ArkinFrom There Towards Now; Intervention for Jewish and Indonesian Post-war Generations | 2027-08-01 |
| NCT05551468Ggz Oost BrabantStayFine: Personalised Relapse Prevention of Anxiety and Mood Disorders in Youths | 2027-11-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Depressive Disorder with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Previous studies with fMRI-neurofeedback in depression have demonstrated a good safety profile and considerable symptom reduction. The goal of this clinical trial is to compare fMRI-neurofeedback plus standard care with standard care in patients with depression.
Participants will either receive standard care, or standard care plus a fMRI neurofeedback training, consisting of 5 neurofeedback training sessions. Symptom severity will be assessed before, immediately after and 6 months after the intervention.
Rationale: Previous studies with fMRI-neurofeedback in depression have demonstrated a good safety profile and considerable symptom reduction but a comparison between standard care and standard care plus fMRI-neurofeedback has not yet been carried out.
Objective: To assess the efficacy of fMRI-neurofeedback plus standard care in comparison with standard care in patients with depression.
Study design: Single-blind RCT. Patients will be randomly allocated to fMRI-neurofeedback plus standard care or standard care. Assessments will be conducted by assessors who are blinded to group allocation.
Patients will be randomised to the two groups using a block randomisation procedure (10 participants per block). Depression severity at baseline (IDS scores) will be used as minimisation variable to ensure equal severity in both groups. The study team will receive a code for group allocation. The study team and patient will be aware of the group allocation (by the nature of the study design), but assessors performing baseline, post-intervention and follow-up assessments will be blinded. During interim analyses, the analysts will remain blinded to the conditions.
If the stopping criterion is reached before the maximal N, any patients already randomised will complete the study and their data will be included in the secondary analyses.
Study population: Currently symptomatic adult patients with depression.
Sample size calculation: A Sequential Bayes Factor (SBF) sampling plan will be used. SBF allows accumulating evidence for (or against) an effect until a certain threshold, i.e. a Bayes Factor (BF), or max N is reached. This is one main advantage compared to frequentist statistics (which is biased against the null hypothesis). Moreover, type-I and type-II error rates do not exist, allowing for flexible stopping rules. This property renders SBF a more resource efficient (in particular for small to medium effect sizes) compared to (traditional frequentist) fixed-N sampling plans. Since type-II errors do not exist in Bayesian statistics, there is no concept of statistical power as in traditional frequentist statistics. However, sensitivity analyses can be carried out a priori to help determining the sample size required to reach a pre-declared level of evidence (given an assumed effect size and a specific prior distribution) that serves as a stopping criterion, For the current sampling plan a BF >= 6 (for either the alternative or the null hypothesis) will be used as a stopping criterion, a value that is in line with recent recommendations. The analysis is carried out with an informed prior t-distribution (t(μ = 0.35, df = 3, r = 0.102)), which reflects a moderate effect size that the investigators would expect given the current design and is in line with suggested informed prior distributions in Psychology. The first interim analysis will be carried out with a minimum N=26 patients per group who have completed the primary endpoint. This minimum N is in line with recommendations for SBF sampling plans. If a BF of 6 for either the alternative or the null is hypothesis is not met, sequential sampling will be carried out with interim tests for every new patient who completes the primary endpoint until either the BF stopping criterion is met or a maximum N=38 is reached (max N). An effect size of Cohen's d = 0.6 was set as the smallest effect size of interest given the restricted resources and previously reported effect sizes reported by pre-registered randomised clinical trials of emotion self-regulation based fMRI neurofeedback. An N max of 38 per group yields 80% sensitivity to detect an effect size of 0.6 under flexible stopping as suggested by simulations (Monte Carlo with 10,000 iterations). Hence, such design is more resource efficient compared to a traditional frequentist fixed-N design (which requires N=45 to reach 80% sensitivity to detect an effect size Cohen's d = 0.6). Further, the false negative rate (i.e. the probability to accumulate erroneously sufficient evidence against the effect and stop the trial early) is only 0.1%, the false positive rate is 12%. The investigators accept this higher false positive rate (compared to the nominal 5%) given that the technology is safe to use. If the BF reaches a value BF>=3 (but smaller than 6) for either the alter-native or null hypothesis, the investigators will revaluate available resources for a potential third sampling phase with N max of 60 per group. The sampling plan thus follows recent recommendations of best practice.
Intervention: FMRI-neurofeedback will be administered in 5 sessions of about 1 hour each, each including a visual stimulation protocol for the localisation of areas responsive to positive emotions and appr. 30 minutes of upregulation training of these areas by means of neurofeedback, using real-time fMRI signals.
Main study parameters/endpoints:
Primary outcome: symptom severity (measured by the clinician-administered Inventory of Depressive Symptomatology) after the intervention.
Secondary outcomes: measures of depression, anxiety and general mental health (Beck Depression Inventory, Self-Efficacy Scale, Hospital Anxiety and Depression Scale, Quality Of Life scale and EuroQol research foundation questionnaire), predictive value of several trait measures (moderator analysis), changes in brain activation patterns measured by fMRI for the neurofeedback group.
In the analysis, outcomes will be controlled for the measurements at baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NF protocol targeting emotion networks (NFE) (plus standard care)
Other: fMRI-based neurofeedback
Continuation of treatment as usual.
Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
Post-intervention score for the 30 item Inventory of Depressive Symptomatology (IDS)
30 item clinician rated depression scale (Rush et al., 1986; Rush, Gullion, Basco, Jarrett, \& Trivedi, 1996)
Time frame: End of intervention: appr. 2 months after baseline
Six month follow-up score for the 30 item Inventory of Depressive Symptomatology (IDS)
30 item clinician rated depression scale (Rush et al., 1986; Rush, Gullion, Basco, Jarrett, \& Trivedi, 1996)
Time frame: 6-month follow-up
Post-intervention score for the Beck Depression Inventory (BDI)
Self-rated depression scale (Beck, Steer, \& Brown, 1996)
Time frame: End of intervention: appr. 2 months after baseline
Six month follow-up score for the Beck Depression Inventory (BDI)
Self-rated depression scale (Beck, Steer, \& Brown, 1996)
Time frame: 6-month follow-up
Post-intervention score for the Hospital Anxiety and Depression Scale (HADS)
Self-rated depression and anxiety scale (Zigmond \& Snaith, 1983). The questionnaire comprises 7 questions for anxiety and 7 for depression. Each scale has a minumum score of 0 and a maximum score of 21. A higher score means more severe anxiety- or depression complaints.
Time frame: End of intervention: appr. 2 months after baseline
Six month follow-up score for the Hospital Anxiety and Depression Scale (HADS)
Self-rated depression and anxiety scale (Zigmond \& Snaith, 1983). The questionnaire comprises 7 questions for anxiety and 7 for depression. Each scale has a minumum score of 0 and a maximum score of 21. A higher score means more severe anxiety- or depression complaints.
Time frame: 6-month follow-up
Post-intervention score for the Quality Of Life scale (QOLS)
Self-rated quality of life scale. A higher score reflects a better quality of life.
Time frame: End of intervention: appr. 2 months after baseline
Six month follow-up score for the Quality Of Life scale (QOLS)
Self-rated quality of life scale. A higher score reflects a better quality of life.
Time frame: 6-month follow-up
Post-intervention score for the EuroQol research foundation questionnaire (EQ-5D-5L)
Self-rated scale of five dimensions of health (Brooks \& Group, 1996)
Time frame: End of intervention: appr. 2 months after baseline
Six month follow-up score for the EuroQol research foundation questionnaire (EQ-5D-5L)
Self-rated scale of five dimensions of health (Brooks \& Group, 1996)
Time frame: 6-month follow-up
Experience sampling of mood states, somatic symptoms and activities using the PsyMate application
One week after baseline and one week before the end of intervention measurement partic-ipants will undergo an experience sampling procedure. Experience sampling will be acquired through the PsyMate application (https://www.psymate.eu) on patients' own or provided smartphones. Participants will thereby digitally complete a brief questionnaire including current affect (positive affect and negative affect items) as well as current context and activ-ities ("daily life activities", "persons present", "physical activity", and "events")
Time frame: 1 week after baseline, 1 week before the end of intervention measurement
Post-intervention score for the Self Efficacy Scale (SES)
Self-rated scale assessing self efficacy (Sherer et al., 1982). The total scores range from 10 to 40. A higher score means more self-efficacy.
Time frame: End of intervention: appr. 2 months after baseline
Six month follow-up score for the Self Efficacy Scale (SES)
Self-rated scale assessing self efficacy (Sherer et al., 1982). The total scores range from 10 to 40. A higher score means more self-efficacy.
Time frame: 6-month follow-up
Ability to self-regulate the target region-of-interest during neurofeedback training
Determine whether participants are able to modulate their BOLD activity in keeping with the neurofeedback
Time frame: Each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8)
Changes in functional parameters (as measured by fMRI) of emotion networks over the course of the intervention
Analysis of fMRI data
Time frame: Each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8)
Brain network activity during neurofeedback training (fMRI analysis)
Determining changes in brain networks (e.g. default mode network)
Time frame: Each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8)
Changes in Profile of Mood States (POMS) after neurofeedback sessions
Measure to address any imminent changes in mood state
Time frame: Before and after each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8)
Started Jan 2023 (actual). Primary completion is estimated for Apr 2027, 51 months after the start.
Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 51 months is above that.
Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2026 → Apr 2027 and completion Apr 2027 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →